Literature DB >> 12218163

TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine.

Jayanthi Manne1, Michael J Mastrangelo, Takami Sato, David Berd.   

Abstract

Administration of a vaccine consisting of autologous melanoma cells modified with a hapten, dinitrophenyl (DNP), induces T cell infiltration of metastatic sites. We have reported an analysis of these infiltrating T cells, indicating that certain TCR-Vbeta gene segments are greatly overexpressed. In this study, we investigate the rearrangement of the TCR-Vbeta as well as the junctional diversity in T cells infiltrating melanoma metastases following treatment with DNP vaccine. In 19 of 26 control specimens, V-D-J length analysis showed the expected polyclonal patterns. In contrast, postvaccine tumors from 9 of 10 patients showed dominant peaks of V-D-J junction size in one or more Vbeta families. Dominant peaks were seen most frequently in six Vbeta families (Vbeta7, 12, 13, 14, 16, and 23) and were never seen in seven others. Further analysis of the oligoclonal Vbeta products showed dominant peaks in the J region as well. Of particular interest was the finding that Vbeta and Jbeta peaks were similar in inflamed metastases obtained at different times or from different sites from the same patient. Although 6 of 10 patients expressed HLA-A1, there was no common pattern of TCR rearrangements among them. Finally, the amplified PCR products from seven of these specimens were cloned and sequenced and the amino acid sequence of the complementarity-determining region 3 was deduced. In six of seven specimens, the same complementarity-determining region 3 sequence was repeated in at least two clones and in five of seven in at least three clones. Our study indicates that DNP vaccine induces the expansion of particular T cell clones that may be agents of its antitumor effects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12218163     DOI: 10.4049/jimmunol.169.6.3407

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  In vivo 6-thioguanine-resistant T cells from melanoma patients have public TCR and share TCR beta amino acid sequences with melanoma-reactive T cells.

Authors:  Cindy L Zuleger; Michael D Macklin; Bret L Bostwick; Qinglin Pei; Michael A Newton; Mark R Albertini
Journal:  J Immunol Methods       Date:  2010-12-21       Impact factor: 2.303

2.  Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma.

Authors:  Juhua Zhou; Mark E Dudley; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunol       Date:  2004-12-15       Impact factor: 5.422

3.  Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma.

Authors:  M Lotem; E Shiloni; I Pappo; O Drize; T Hamburger; R Weitzen; R Isacson; L Kaduri; S Merims; S Frankenburg; T Peretz
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

4.  Array-based comparative genomic hybridization analysis reveals chromosomal copy number aberrations associated with clinical outcome in canine diffuse large B-cell lymphoma.

Authors:  Arianna Aricò; Serena Ferraresso; Silvia Bresolin; Laura Marconato; Stefano Comazzi; Geertruy Te Kronnie; Luca Aresu
Journal:  PLoS One       Date:  2014-11-05       Impact factor: 3.240

5.  Compositional characteristics of human peripheral TRBV pseudogene rearrangements.

Authors:  Bin Shi; Long Ma; Xiaoyan He; Peipei Wu; Peng Wang; Xiaomei Wang; Rui Ma; Xinsheng Yao
Journal:  Sci Rep       Date:  2018-04-12       Impact factor: 4.379

6.  Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients.

Authors:  Federico Serana; Alessandra Sottini; Luigi Caimi; Belinda Palermo; Pier Giorgio Natali; Paola Nisticò; Luisa Imberti
Journal:  J Transl Med       Date:  2009-03-24       Impact factor: 5.531

7.  T-cell clonotypes in cancer.

Authors:  Per Thor Straten; David Schrama; Mads Hald Andersen; Jürgen C Becker
Journal:  J Transl Med       Date:  2004-04-08       Impact factor: 5.531

Review 8.  Hapten-induced contact hypersensitivity, autoimmune reactions, and tumor regression: plausibility of mediating antitumor immunity.

Authors:  Dan A Erkes; Senthamil R Selvan
Journal:  J Immunol Res       Date:  2014-05-15       Impact factor: 4.818

Review 9.  T Cell Receptor Profiling in Type 1 Diabetes.

Authors:  Laura M Jacobsen; Amanda Posgai; Howard R Seay; Michael J Haller; Todd M Brusko
Journal:  Curr Diab Rep       Date:  2017-10-11       Impact factor: 4.810

10.  Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines.

Authors:  Sruthi Ravindranathan; Khue G Nguyen; Samantha L Kurtz; Haven N Frazier; Sean G Smith; Bhanu Prasanth Koppolu; Narasimhan Rajaram; David A Zaharoff
Journal:  Breast Cancer Res       Date:  2018-10-22       Impact factor: 6.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.